L-Theanine, 5-Hydroxytryptophan (5-HTP) and melatonin have all been shown to independently improve sleep quality and quantity, and/or lessen anxiety. L-Theanine is an amino acid found almost exclusively in tea,1 which influences the central nervous system through a number of mechanisms, primarily by influencing levels of the neurotransmitters dopamine,2 gamma-aminobutyric acid (GABA),3,4 serotonin,5,6 norepinephrine6 and glutamate.7,8 These effects cause a significant increase in alpha brain wave activity, indicative of a state of wakeful relaxation, increased performance under stress, improved learning and concentration, as well as decreased anxiety.1,9
5-HTP is the intermediary between L-tryptophan and serotonin, a key neurotransmitter associated with sleep, mood and anxiety.10-12 5-HTP bypasses the rate-limiting enzyme tryptophan hydroxylase, which normally limits the conversion of tryptophan to serotonin.13
Melatonin is also closely related, and is formed by conversion of serotonin in the pineal gland. Known to regulate many biological rhythms, including the circadian cycle, melatonin has shown clinical benefit for inducing sleep or adjusting sleep cycles.14 Randomized trials have found it to reduce sleep onset latency and improve perceived quality of sleep, without impairing daytime psychomotor performance.15,16
- Addresses every facet of insomnia: difficulty initiating sleep, difficulty maintaining
sleep, waking too early in the morning and waking groggy
- Reduces anxiety and nervous system excitation, which can inhibit sleep
- Safe without the side effects of prescription or over-the-counter (OTC) medications
- Convenient and fast acting
- Delicious tropical fruit flavoured chewable
Serving Size: 2 chewable tablets
Servings per Container: 45
Each Tablet Contains:
Suntheanine® L-Theanine................................................................... 100 mg
L-5-Hydroxytryptophan (5-HTP) (Griffonia simplicifolia) (seed)....... 15 mg
Melatonin............................................................................................ 1.5 mg
Non-medicinal Ingredients: Organic cane juice, stearic acid, xylitol, silica, natural flavours(pineapple, banana, pomegranate, mango, passion fruit, peach), citric acid, vegetable grade magnesium stearate (lubricant).
Contains no artificial preservatives, colours or sweeteners and no dairy, soy, wheat or yeast.
Chew 2 tablets 30–45 minutes before bedtime or as directed by a health care practitioner.
While no specific contraindication exists or is predicted, data is lacking for use during pregnancy, lactation, and in children, and the dosage may need to be reduced for those less than 18. Consult a health care practitioner prior to use if you have a hormonal disorder, diabetes, liver or kidney disease, cerebral palsy, seizure disorders, migraine, depression and/or hypertension17 or if you have scleroderma.18,19 Do not drive or use machinery for 5 hours after taking melatonin.20
L-Theanine is known to have a hypotensive effect in some individuals, and concomitant use of antihypertensive drugs may potentiate their activity.21 Consult a health care practitioner prior to use if you are taking carbidopa or drugs/supplements with serotonergic activity.22 These may include, but are not limited to L-tryptophan, S-adenosylmethionine (SAMe), St. John’s wort, antidepressants, pain killers, over-the-counter cough and cold medication containing dextromethorphan, antinausea medication and antimigraine medication. If symptoms worsen or persist for more than 3 weeks (chronic insomnia), consult a health care practitioner. Some people may experience diarrhea, nausea, vomiting and abdominal pain.23,24 Discontinue use if you show signs of weakness, oral ulcers, skin changes or abdominal pain accompanied by severe muscle pain.22 Do not use if you are taking blood pressure, immunosuppressive or sedative/hypnotic medication.17
- Juneja LR, Chu DC, Okubo T, Nagato Y, Yokogoshi H. L-Theanine - a unique amino acid of green tea and its relaxation effect in humans. Trends in Food Science & Technology, 1999.10 (2):199–204.
- Yokogoshi H, Kobayashi M, Mochizuki M, Terashima T. Effect of theanine, r-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. Neurochem Res.1998 May;23(5):667-73.
- Kimura R, Murata T. Influence of alkylamides of glutamic acid and related compounds on the central nervous system. I. Central depressant effect of theanine. Chem Pharm Bull. (Tokyo). 1971 Jun;19(6):1257-61.
- Alternative Medicine Review. Gamma-Aminobutyric Acid (GABA), Monograph. Altern Med Rev. 2007 Sep;12(3):274-9.
- Yokogoshi H, Mochizuki M, Saitoh K. Theanine-induced reduction of brain serotonin concentration in rats. Biosci Biotechnol Biochem. 1998 Apr;62(4):816-7.
- Kimura R, Murata T. Effect of theanine on norepinephrine and serotonin levels in rat brain. Chem Pharm Bull (Tokyo). 1986 Jul;34(7):3053-7.
- Kakuda T. Neuroprotective effects of green tea components theanine and catechins. Biol Pharm Bull. 2002 Dec;25(12):1513-8.
- Kimura K, Ozeki M, Juneja LR, Ohira H. L-theanine reduces psychological and physiological stress responses. Biol Psychol. 2007 Jan;74(1):39-45.
- Nobre AC, Rao A, Owen GN. L-theanin, a natural constituent in tea, and its effect on mental state. Asia Pac J Clin Nutr. 2008;17 Suppl:167-8.
- Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev. 1998;3(4):271-80.
- Wyatt RJ, Zarcone V, Engelman K, Dement WC, Snyder F, Sjoerdsma A. Effects of 5-hydroxytryptophan on the sleep of normal human subjects. Electroencephalogr Clin Neurophysiol. 197 Jun;30(6): 505-9.
- Soulairac A, Lambinet H. [Clinical studies of the effect of the serotonin precursor, L-5-Hydroxytryptophan, on sleep disorders]. Schweiz Rundsch Med Prax. 1998 Aug 23;77(34A):19-23.
- Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev. 2002;(1):CD003198.
- Kunz D, Mahlberg R, Muller C, Tilman A, Bes F. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. J Clin Endocrinol Metab. 2004 Jan;89(1):128-34.
- Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, Zisapel N. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next day alertness outcomes. Curr Med Res Opin. 2007 Oct;23(10):2597-605.
- Wade AG, Ford I, Crawford G, McConnachie A, Nir T, Laudon M, Zisapel N. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010 Aug 16;8:51.
- IOM 2004: Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements. Prototype monograph on melatonin. Dietary Supplement Ingredient Prototype Monographs, Developed as Examples for the Report Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine and the National Research Council of the National Academies, Washington (DC): National Academies Press 2004: D1-D71.
- Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med. 1980 Oct 2;303(14):782-7.
- Joly P, Lampert A, Thomine E, Lauret P. Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. J Am Acad Dermatol. 1991 Aug;25(2 Pt 1):332-3.
- Avery D, Lenz M, Landis C. Guidelines for prescribing melatonin. Annals of Medicine. 1998;30(1):122-30.
- Yokogoshi H, Kobayashi M. Hypotensive effect of gamma-glutamylmethylamide in spontaneously hypertensive rats. Life Sci. 1998;62(12):1065-8.
- Singhal AB, Caviness VS, Begleiter AF, Mark EJ, Rordorf G, Koroshetz WJ. Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology. 2002 Jan 8;58(1):130-3.
- Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. J Clin Psychopharmacol. 1987;7:127-37.
- Poldinger W, Calanchini B, Schwarz W. A functional-dimensional approach to depression: serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine. Psychopathology. 1991;24(2):53-81.